Skip to main content
. 2018 Jun 15;16(3):3063–3069. doi: 10.3892/ol.2018.8970

Figure 3.

Figure 3.

Confirmation DAB2 as the target of miR-106b in HCC. (A) Prediction of the binding site of miR-106b with DAB2. (B) Detection of luciferase activities in Hep3B cell line after transfection with DAB2-3-UTR-wild (wild-type) or DAB2-3-UTR-mutant (mut-type). (C and D) Relative DAB2 mRNA and protein expression tested using qPCR and western blot analysis in Hep3B cell line (*P<0.05 vs. control mimic; #P<0.05; **P<0.01 vs. control inhibitor). (E) The negative correlation between DAB2 and miR-106b expression in HCC tissues (r=−0.7456, P<0.001). HCC, hepatocellular carcinoma.